WO2024049361A1 - Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates - Google Patents
Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates Download PDFInfo
- Publication number
- WO2024049361A1 WO2024049361A1 PCT/TH2022/000032 TH2022000032W WO2024049361A1 WO 2024049361 A1 WO2024049361 A1 WO 2024049361A1 TH 2022000032 W TH2022000032 W TH 2022000032W WO 2024049361 A1 WO2024049361 A1 WO 2024049361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active substances
- cannabinoid
- based compositions
- acid
- leaves
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000013543 active substance Substances 0.000 title claims abstract description 46
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 39
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 39
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 19
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 19
- 235000009120 camo Nutrition 0.000 claims abstract description 19
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 19
- 239000011487 hemp Substances 0.000 claims abstract description 19
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 3
- 241000218236 Cannabis Species 0.000 claims description 19
- 244000025254 Cannabis sativa Species 0.000 claims description 18
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 claims description 14
- 244000286838 Eclipta prostrata Species 0.000 claims description 13
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 12
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 12
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 12
- 229950011318 cannabidiol Drugs 0.000 claims description 12
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 12
- 240000000230 Chromolaena odorata Species 0.000 claims description 11
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 10
- HMUJXQRRKBLVOO-AWEZNQCLSA-N 4'-methoxy-5,7-dihydroxyflavanone Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 HMUJXQRRKBLVOO-AWEZNQCLSA-N 0.000 claims description 10
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 10
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 10
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 10
- 229960004242 dronabinol Drugs 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 10
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 9
- 240000003152 Rhus chinensis Species 0.000 claims description 8
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 8
- 229940065144 cannabinoids Drugs 0.000 claims description 8
- 244000146462 Centella asiatica Species 0.000 claims description 7
- 235000004032 Centella asiatica Nutrition 0.000 claims description 7
- 229930003935 flavonoid Natural products 0.000 claims description 7
- 235000017173 flavonoids Nutrition 0.000 claims description 7
- 150000002215 flavonoids Chemical class 0.000 claims description 7
- FRISOFZUHCOQEC-UHFFFAOYSA-N 1-(6-hydroxy-2,3,4-trimethoxyphenyl)-3-(4-methoxyphenyl)propenone Natural products C1=CC(OC)=CC=C1C=CC(=O)C1=C(O)C=C(OC)C(OC)=C1OC FRISOFZUHCOQEC-UHFFFAOYSA-N 0.000 claims description 5
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 5
- BYNYZQQDQIQLSO-UHFFFAOYSA-N 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-6-methoxychromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=C(OC)C=C2C1=O BYNYZQQDQIQLSO-UHFFFAOYSA-N 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 5
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 5
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 5
- 229920002079 Ellagic acid Polymers 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 5
- LUCQSVLCPJUJRN-UHVRHXOTSA-N Naringerin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)c1cc(O)c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c1 LUCQSVLCPJUJRN-UHVRHXOTSA-N 0.000 claims description 5
- ZVOSNTPXWLRWJG-UHFFFAOYSA-N Odoratin Natural products CC1C2CCC3(C)C(OC(=O)C=C3C2CCC1=O)c4cocc4 ZVOSNTPXWLRWJG-UHFFFAOYSA-N 0.000 claims description 5
- ZFCRHGITKWEXDY-UHFFFAOYSA-N Odoratin I* Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(O)C(O)CC12 ZFCRHGITKWEXDY-UHFFFAOYSA-N 0.000 claims description 5
- 241000920652 Quercus lusitanica Species 0.000 claims description 5
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 claims description 5
- 229940011658 asiatic acid Drugs 0.000 claims description 5
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 claims description 5
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 5
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004132 ellagic acid Nutrition 0.000 claims description 5
- 229960002852 ellagic acid Drugs 0.000 claims description 5
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 claims description 5
- 235000004515 gallic acid Nutrition 0.000 claims description 5
- 229940074391 gallic acid Drugs 0.000 claims description 5
- 229920002824 gallotannin Polymers 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 claims description 5
- 229940011656 madecassic acid Drugs 0.000 claims description 5
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 claims description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 5
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 5
- 150000007965 phenolic acids Chemical class 0.000 claims description 5
- 229920001864 tannin Polymers 0.000 claims description 5
- 235000018553 tannin Nutrition 0.000 claims description 5
- 239000001648 tannin Substances 0.000 claims description 5
- -1 eupatol Chemical compound 0.000 claims description 4
- 206010040880 Skin irritation Diseases 0.000 claims description 3
- 230000036556 skin irritation Effects 0.000 claims description 3
- 231100000475 skin irritation Toxicity 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims 8
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 4
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 41
- 206010052428 Wound Diseases 0.000 abstract description 40
- 230000029663 wound healing Effects 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 206010040872 skin infection Diseases 0.000 abstract description 4
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 208000037976 chronic inflammation Diseases 0.000 abstract description 3
- 230000006020 chronic inflammation Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 240000004308 marijuana Species 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 240000006053 Garcinia mangostana Species 0.000 description 2
- 235000017048 Garcinia mangostana Nutrition 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010057619 Infective tenosynovitis Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 244000226566 Psoralea corylifolia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940005582 gotu kola extract Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the invention relates to cannabinoid-based compositions comprising active substances from cannabis and/or hemp in conjunction with active substances from other genera, in combination for wounds healing and thereof.
- wounds from injuries are uncontrollable and difficult to prevent, especially for the elderly or patients with medical condition or low immunity that small or large wounds, or scratching that cause wounds on the skin are more prone to incidence while some wounds can heal on their own.
- wound dressing or wound care is of paramount importance, as can be seen in many products that help promote wound care in the form of equipment, materials, products, from devices or products for wound care and dressings, external medicine for wounds, bandages, and products to apply when the wound starts to dry so that the wound heals without scarring and it helps strengthen the skin cells in the area, as well as provide an even skin tone.
- Another important aspect of wound healing is to prevent wound infection because if the wound gets infected, in addition to a longer duration of treatment, the wound may spread widely and damage the skin tissue. However, if the infection is severe or chronic, it can be widespread and difficult to heal, which may even result in the need to cut off some of the more damaged tissue. To prevent further skin damage from spreading to other areas, treatments to prevent wound infection include using herbal remedies directly and herbal medicine recipes that help in healing wounds to heal faster. According to the examination, it has been found that some pieces of work are applying for protection and are close to some composition as follows:
- the Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections.
- the Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections.
- 1603001846 refers to a cream containing herbal extracts containing false daisy extract, mangosteen peel extract, Gotu Kola extract mixed with sodium lauryl sulfate, propylene glycol, stearyl alcohol, cetyl alcohol, coconut oil, concentrated parabens, distilled water, with the following cream manufacturing processes: by extracting false daisy, mangosteen peel, and Gotu Kola and mixing the extracts at the ratio of 3:1 :1 by weight and mix with other substances, stir, and adjust the pH to be between 6.0-7.0.
- the United States patent publication no. US20210236687A1 refers to a woundmanagement component containing a combination of full-spectrum cannabinoids and at least one hemostatic agent. This includes a hemostasis-level astringent, a hemostasis level, and a hemostasis mechanism level.
- the composition may also include at least a chemical infiltration enhancer that amplifies the absorption of cannabinoids, at least one topical drug to prolong the pharmacological activity of the cannabinoids, at least one antibacterial agent, and at least one antifungal agent, as well as means of delivery of wound management composition and kits.
- the foreign patent publication no. WO2019202356A1 refers to the composition with cannabidiol supplementation and anti-inflammatory herbal extracts that inhibit COX (cyclooxygenase) and LOX (lipoxygenase), Psoralea Corylifolia or Betulin or rosemary leaf extract or licorice extract (Glycyrrhiza Glabra) with a small amount of cannabidiol of not more than 1.0% by volume.
- the therapeutic effect of each herbal extract contains ingredients that can be used to heal skin inflammation.
- compositions or products containing different herbs are used to treat different wounds to meet the needs of symptoms and wounds.
- the inventor has invented a chemical compositions that contain active substances from cannabis or hemp for inhibiting bacteria that affects the skin in order to heal wounds, inhibit bacterial infection, help the blood to clot in order to allow the wounds to heal, and result in quick-drying and inhibiting skin irritation, particularly suitable for patients with low immunity, such as those with diabetes, shingles, and patients after surgery, etc.
- the cannabinoid-based compositions are developed to provide unique properties to help the blood clot including the inhibition of bacterial infection.
- the aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other genera in appropriate quantities.
- the preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.
- the purpose of this invention is to provide a cannabinoid-based composition for medical use.
- the unique property of such composition is function in coagulating blood together with inhibiting bacterial infection, which directly affects the healing of wounds, reducing inflammation and wound pain that may spread and damage the tissues of the wound. This makes the wound heal and the wound is covered to prevent getting pathogens faster.
- the cannabinoid-based compositions for medical use contain active substances from cannabis or hemp that are effective against gram-positive, gram-negative bacteria and fungi that cause skin infections and can help reduce inflammation together with the composition of active substances of anisic acid, flavonoids, and triterpenoids that can be found from Siam weed leaves, False daisy leaves, centella asiatica, nutgall, etc., which are characterized in that they help stop bleeding, increase blood clotting to prevent and reduce blood loss from wounds, inhibit skin irritation and improve the effectiveness of wound healing, including reducing scarring.
- the cannabinoid-based compositions include:
- the appropriate amount of active substances from cannabis or hemp is 20-80% by weight, together with the active substances from other genera in the appropriate amount of 20-80% by weight.
- composition requires the extraction process with hexane, ethyl acetate or other polar solvents such as acetone, ethanol, methanol, or water or a supercritical fluid extraction method, and then, to obtain a chemical mixture, it is subjected to a purification process by precipitation.
- Active substances from cannabis or hemp may be selected from any one or more of cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof.
- cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof.
- Active substances from other genera may be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves, centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid, in combination thereof.
- compositions were sent to the accredited laboratory for testing (In Vitro) to test their activity against bacteria and virus and they were found to have a beneficial effect on inhibiting gram-positive skin bacteria and herpesvirus with low concentrations for the production of the compositions for use in the treatment of patients by choosing to develop into a cream or gel form for ease of use, storage, and portability of users and with appropriate concentrations to test the side effects of skin wounds and surrounding wounds. All wounds were healed from the use of the compositions in a shorter time than patients expected compared to the length of time that patients had been treated with other medicines prior to receiving the compositions in this study, and there were no adverse effects on the wound healing and other surrounding skin as shown in the table:
- the cannabinoid-based composition in cream or gel form can be used to treat patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation. It was observed that the rapid response phase of blood coagulation and wound healing improved within 3 to 7 days, and treatment was completed within 2-8 weeks, depending on the individual patient's condition. However, all of them recovered from the use of this composition in a shorter time than patients expected compared to the length of time patients were treated with other medicines before receiving the medicines in this study and had no side effects on the wound and other surrounding areas.
- cannabinoid-based compositions comprise active substances that provide a direct effect on healing and inhibiting pathogens, balancing the skin system, and immune system, reducing inflammation, and reducing pain, through the endocannabinoid system and a group of ion channels on the cell membrane, TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation, the patients and their caregivers may use them to support patient care in conjunction with the current mainstream treatment. They also reduce the chance of organ loss such as in the feet and legs. In the case of patients with diabetic foot, they will recover faster and have fewer side effects from the disease. These are significant parts of gaining opportunities and holistic quality of life for patients and their caregivers. Best Mode of the Invention
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The cannabinoid -based compositions according to this invention are developed to provide unique properties to help the blood clot, including the inhibition of bacterial infection. The aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other genera in appropriate quantities. The preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpes virus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.
Description
MIXTURES OF CANNABINOID-BASED COMPOSITIONS AND ACTIVE SUBSTANCES
FROM OTHER GENERA FOR MEDICAL APPLICATIONS AND ASSOCIATES
Field of the Invention
The invention relates to cannabinoid-based compositions comprising active substances from cannabis and/or hemp in conjunction with active substances from other genera, in combination for wounds healing and thereof.
Background of the Invention
Skin wounds from injuries are uncontrollable and difficult to prevent, especially for the elderly or patients with medical condition or low immunity that small or large wounds, or scratching that cause wounds on the skin are more prone to incidence while some wounds can heal on their own. However, as some wounds may require medication and take a long time to dry and heal completely, wound dressing or wound care is of paramount importance, as can be seen in many products that help promote wound care in the form of equipment, materials, products, from devices or products for wound care and dressings, external medicine for wounds, bandages, and products to apply when the wound starts to dry so that the wound heals without scarring and it helps strengthen the skin cells in the area, as well as provide an even skin tone.
Another important aspect of wound healing is to prevent wound infection because if the wound gets infected, in addition to a longer duration of treatment, the wound may spread widely and damage the skin tissue. However, if the infection is severe or chronic, it can be widespread and difficult to heal, which may even result in the need to cut off some of the more damaged tissue. To prevent further skin damage from spreading to other areas, treatments to prevent wound infection include using herbal remedies directly and herbal medicine recipes that help in healing wounds to heal faster. According to the examination, it has been found that some pieces of work are applying for protection and are close to some composition as follows:
The Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections.
The Thai Petty Patent Application No. 1603001846 refers to a cream containing herbal extracts containing false daisy extract, mangosteen peel extract, Gotu Kola extract mixed with sodium lauryl sulfate, propylene glycol, stearyl alcohol, cetyl alcohol, coconut oil, concentrated parabens, distilled water, with the following cream manufacturing processes: by extracting false daisy, mangosteen peel, and Gotu Kola and mixing the extracts at the ratio of 3:1 :1 by weight and mix with other substances, stir, and adjust the pH to be between 6.0-7.0.
The United States patent publication no. US20210236687A1 refers to a woundmanagement component containing a combination of full-spectrum cannabinoids and at least one hemostatic agent. This includes a hemostasis-level astringent, a hemostasis level, and a hemostasis mechanism level. The composition may also include at least a chemical infiltration enhancer that amplifies the absorption of cannabinoids, at least one topical drug to prolong the pharmacological activity of the cannabinoids, at least one antibacterial agent, and at least one antifungal agent, as well as means of delivery of wound management composition and kits.
The foreign patent publication no. WO2019202356A1 refers to the composition with cannabidiol supplementation and anti-inflammatory herbal extracts that inhibit COX (cyclooxygenase) and LOX (lipoxygenase), Psoralea Corylifolia or Betulin or rosemary leaf extract or licorice extract (Glycyrrhiza Glabra) with a small amount of cannabidiol of not more than 1.0% by volume. The therapeutic effect of each herbal extract contains ingredients that can be used to heal skin inflammation.
As mentioned above, it is seen that pharmaceutical composition or products containing different herbs are used to treat different wounds to meet the needs of symptoms and wounds. The inventor has invented a chemical compositions that contain active substances from cannabis or hemp for inhibiting bacteria that affects the skin in order to heal wounds, inhibit bacterial infection, help the blood to clot in order to allow the wounds to heal, and result in quick-drying and inhibiting skin irritation, particularly suitable for patients with low immunity, such as those with diabetes, shingles, and patients after surgery, etc.
Summary of the Invention
The cannabinoid-based compositions are developed to provide unique properties to help the blood clot including the inhibition of bacterial infection. The aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other
genera in appropriate quantities. The preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.
The purpose of this invention is to provide a cannabinoid-based composition for medical use. The unique property of such composition is function in coagulating blood together with inhibiting bacterial infection, which directly affects the healing of wounds, reducing inflammation and wound pain that may spread and damage the tissues of the wound. This makes the wound heal and the wound is covered to prevent getting pathogens faster.
Detailed Description of the Invention
The cannabinoid-based compositions for medical use contain active substances from cannabis or hemp that are effective against gram-positive, gram-negative bacteria and fungi that cause skin infections and can help reduce inflammation together with the composition of active substances of anisic acid, flavonoids, and triterpenoids that can be found from Siam weed leaves, False daisy leaves, centella asiatica, nutgall, etc., which are characterized in that they help stop bleeding, increase blood clotting to prevent and reduce blood loss from wounds, inhibit skin irritation and improve the effectiveness of wound healing, including reducing scarring.
The cannabinoid-based compositions include:
The appropriate amount of active substances from cannabis or hemp is 20-80% by weight, together with the active substances from other genera in the appropriate amount of 20-80% by weight.
The preparation process of such composition requires the extraction process with hexane, ethyl acetate or other polar solvents such as acetone, ethanol, methanol, or water or a supercritical fluid extraction method, and then, to obtain a chemical mixture, it is subjected to a purification process by precipitation.
Active substances from cannabis or hemp may be selected from any one or more of cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof.
Active substances from other genera may be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves, centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid, in combination thereof.
Research results of synergistic reaction properties of cannabinoid, anisic acid, flavonoid, and triterpenoids were obtained by testing a wide range of patients, such as those with diabetes, shingles, and patients after surgery, with the cannabinoid-based composition for inhibition of skinaffecting bacteria at appropriate total concentrations. In this study, 34 patients were treated in 6 groups, 16 of which were bedridden wounds, 5 with diabetic ulcers, 9 with fresh wounds, 2 with skin and subcutaneous tendon infections, 1 with herpetic wounds, and 1 with psoriasis.
According to the research, the compositions were sent to the accredited laboratory for testing (In Vitro) to test their activity against bacteria and virus and they were found to have a beneficial effect on inhibiting gram-positive skin bacteria and herpesvirus with low concentrations for the production of the compositions for use in the treatment of patients by choosing to develop into a cream or gel form for ease of use, storage, and portability of users and with appropriate concentrations to test the side effects of skin wounds and surrounding wounds. All wounds were healed from the use of the compositions in a shorter time than patients expected compared to the length of time that patients had been treated with other medicines prior to receiving the compositions in this study, and there were no adverse effects on the wound healing and other surrounding skin as shown in the table:
In conclusion, the cannabinoid-based composition in cream or gel form can be used to treat patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation. It was observed that the rapid response phase of blood coagulation and wound healing improved within 3 to 7 days, and treatment was completed within 2-8 weeks, depending on the individual patient's condition. However, all of them recovered from the use of this composition in a shorter time than patients expected compared to the length of time patients were treated with other medicines before receiving the medicines in this study and had no side effects on the wound and other surrounding areas.
As the cannabinoid-based compositions comprise active substances that provide a direct effect on healing and inhibiting pathogens, balancing the skin system, and immune system, reducing inflammation, and reducing pain, through the endocannabinoid system and a group of ion channels on the cell membrane, TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation, the patients and their caregivers may use them to support patient care in conjunction with the current mainstream treatment. They also reduce the chance of organ loss such as in the feet and legs. In the case of patients with diabetic foot, they will recover faster and have fewer side effects from the disease. These are significant parts of gaining opportunities and holistic quality of life for patients and their caregivers. Best Mode of the Invention
As described in Detailed Description of the Invention section.
Claims
1. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they stop bleeding and help the blood clot.
2. The cannabinoid-based compositions according to claim 1, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
3. The cannabinoid-based compositions according to claim 1, wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
4. The cannabinoid-based compositions according to claim 1 , wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
5. The cannabinoid-based compositions according to claim 1, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
6. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp combined with active substances from other genera, which are characterized in that they help inhibit skin irritation.
7. The cannabinoid-based compositions according to claim 6, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
8. The cannabinoid-based compositions according to claim 6, wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
9. The cannabinoid-based compositions according to claim 6, wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
10. The cannabinoid-based compositions according to claim 6, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
11. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they inhibit bacteria.
12. The cannabinoid-based compositions according to claim 11, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
13. The cannabinoid-based compositions according to claim 11 , wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
14. The cannabinoid-based compositions according to claim 11, wherein the active substances from cannabis and/or hemp can be selected, from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) in combination thereof.
15. The cannabinoid-based compositions according to claim 11, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
16. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they reduce inflammation and muscle pain.
17. The cannabinoid-based compositions according to claim 16, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
18. The cannabinoid-based compositions according to claim 16, wherein the appropriate concentration of active substances from other genera, is 20-80% by weight.
19. The cannabinoid-based compositions according to claim 16, wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
20. The cannabinoid-based compositions according to claim 16, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TH2022/000032 WO2024049361A1 (en) | 2022-09-01 | 2022-09-01 | Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TH2022/000032 WO2024049361A1 (en) | 2022-09-01 | 2022-09-01 | Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024049361A1 true WO2024049361A1 (en) | 2024-03-07 |
Family
ID=84331575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TH2022/000032 WO2024049361A1 (en) | 2022-09-01 | 2022-09-01 | Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024049361A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019155337A1 (en) * | 2018-02-06 | 2019-08-15 | Scicann Therapeutics Inc. | Compositions comprising a cannabinoid and punicalagin and methods of use thereof |
WO2019202356A1 (en) | 2018-04-17 | 2019-10-24 | Cebadex SE | The enhancing effect of cannabidiol (cbd) to anti-inflammatory plant extracts having a dual inhibitory effect on cox and lox |
US20210077422A1 (en) * | 2019-03-19 | 2021-03-18 | Spirit Songs Botanicals | Cannabinoid formulation including synergistic organosulphur compounds |
US20210236687A1 (en) | 2020-01-31 | 2021-08-05 | Pac-Dent, Inc. | Cannabinoid-based oral hemostatic compositions |
-
2022
- 2022-09-01 WO PCT/TH2022/000032 patent/WO2024049361A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019155337A1 (en) * | 2018-02-06 | 2019-08-15 | Scicann Therapeutics Inc. | Compositions comprising a cannabinoid and punicalagin and methods of use thereof |
WO2019202356A1 (en) | 2018-04-17 | 2019-10-24 | Cebadex SE | The enhancing effect of cannabidiol (cbd) to anti-inflammatory plant extracts having a dual inhibitory effect on cox and lox |
US20210077422A1 (en) * | 2019-03-19 | 2021-03-18 | Spirit Songs Botanicals | Cannabinoid formulation including synergistic organosulphur compounds |
US20210236687A1 (en) | 2020-01-31 | 2021-08-05 | Pac-Dent, Inc. | Cannabinoid-based oral hemostatic compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oguntibeju | Medicinal plants and their effects on diabetic wound healing | |
RU2750286C2 (en) | Composition for local application stimulating wound healing | |
WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
AU2020103238A4 (en) | A formulation for treatment of diabetic complications and method of preparation thereof | |
US20230055582A1 (en) | Compositions and methods for treatment of inflammatory conditions and diseases of the skin | |
CN110292602A (en) | Yellow burn oil formula of a kind of compound five and preparation method thereof | |
Jamil et al. | Review Effect of Aloe vera on Wound Healing: Review: Effect of Aloe vera on Wound Healing | |
Elegbede et al. | Effect of fermented and green Aspalathus linearis extract loaded hydrogel on surgical wound healing in Sprague Dawley rats | |
Muhammed et al. | Effect of application of Fenugreek (Trigonella foenum-graecum) on skin wound healing in rabbits | |
WO2008150246A1 (en) | Herbal haemostatic composition | |
Ukwueze et al. | Evaluation of the cutaneous wound healing activity of solvent fractions of Chromolaena odorata Linn | |
WO2024049361A1 (en) | Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates | |
CN110038056A (en) | A kind of compound Chinese Gall ointment and preparation method thereof for treating pet limbs inflammatory swelling | |
WO2007031364A1 (en) | Dressing material comprising active substances | |
CN105194330A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
CN110787104A (en) | Compound traditional Chinese medicine toothpaste and preparation method and application thereof | |
Bairy | Wound healing potentials of plant products | |
US11154583B2 (en) | Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies | |
CN106902114A (en) | A kind of pharmaceutical composition for treating acute soft tissue injury | |
Mohammad | Histological and surgical study of the henna on wound healing in animals Field (Sheep) | |
Iskandar et al. | Centella asiatica extract effect on postoperative wound healing | |
CN107536937A (en) | A kind of external application Chinese medicine decoction for treating skin disease and onychomycosis and preparation method thereof | |
Yang et al. | Wound healing activity of avocado peel ointment against second degree burn wound | |
CN103919837A (en) | Traditional Chinese medicine with hemostatic effect | |
Trieu et al. | Wound-healing potential of topical application of preparations from Noni (Morinda citrifolia L.) leaf extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22802302 Country of ref document: EP Kind code of ref document: A1 |